Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Treatment options for managing atherogenic dyslipidemia and fatty liver disease.

Authors
  • Rizzo, Manfredi
  • Montalto, Giuseppe
  • Al-Rasadi, Khalid
Type
Published Article
Journal
Expert Opinion on Pharmacotherapy
Publisher
Informa UK (Taylor & Francis)
Publication Date
Jun 01, 2014
Volume
15
Issue
8
Pages
1065–1068
Identifiers
DOI: 10.1517/14656566.2014.902051
PMID: 24673432
Source
Medline
Keywords
License
Unknown

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30% of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, while there is reluctance to use statins in patients with suspected or established chronic liver disease. Several other therapeutic options are potentially available, and more data are expected from new peroxisome proliferator-activated receptor agonists and incretin-based therapies.

Report this publication

Statistics

Seen <100 times